Quantcast
Last updated on April 17, 2014 at 15:48 EDT

Latest Virus-like particle Stories

2014-03-25 08:30:28

ROCKVILLE, Md., March 25, 2014 /PRNewswire/ -- VLP Therapeutics, Inc. ("VLP"), a Rockville-based biotechnology company focusing on the research and development of next generation antibody agents and therapeutic as well as preventive vaccines based upon a novel and proprietary i- VLP technology (which stands for "inserted alpha virus like particle"), today announced that Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder and former Chair, Chief Executive Officer and Chief Scientific Officer of...

2014-03-07 12:25:48

Instrumentation Allows for High Resolution Mass and Size Analysis of Proteins, Antibody Aggregates, Viruses/Vaccines/VLPs, Polymers, and Nanoparticles SHOREVIEW, Minn., March 7, 2014 /PRNewswire/ -- TSI, a worldwide leader in precision measurement instrumentation, announces the launch of its new MacroIMS(TM) Macroion Spectrometer. The MacroIMS Macroion Mobility Spectrometer 3982 is a powerful new tool for rapid, high-resolution molecular size and mass analysis of macromolecules....

2014-01-29 00:20:55

SINGAPORE and ZURICH, January 29, 2014 /PRNewswire/ -- Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that their influenza vaccine (gH1-Qbeta) met its primary end point for immunogenicity (seroconversion based on haemaglutination inhibition titres according to FDA criteria) in the Phase 1 clinical trial in healthy Asian volunteers. The induced immune response showed good cross-reactivity to recent...

2014-01-23 23:05:00

GIA announces the release of a trend report on Virus-Like Particles (VLPs). Market for Virus-Like Particles (VLPs) is projected to witness growth led by technological advancements in vaccine development. San Jose, California (PRWEB) January 23, 2014 Virus-like particles (VLPs) bear high structural resemblance to viruses, though completely non-infectious in nature due to the absence of viral genetic material. Despite lacking DNA material, VLPs retain key immunological characteristics of...

2013-11-05 08:36:07

SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Pfenex Inc. today announced that it has awarded Paragon Bioservices a contract for the current Good Manufacturing Practice (cGMP) manufacturing of its rPA based anthrax vaccine. Paragon Bioservices will implement the cGMP-ready Pfenex Expression Technology(TM)-based production process that has been developed at Pfenex, through its vaccines division. Funding will be provided by the Department of Health and Human Services (HHS), through the...

2013-09-18 08:28:52

OSAKA, Japan and QUEBEC CITY, Canada, Sept. 18, 2013 /PRNewswire/ - Mitsubishi Tanabe Pharma Corporation (TSE: 4508) ("Mitsubishi Tanabe Pharma" or "MTPC") and Medicago Inc. (TSX: MDG) announced today the completion of the previously announced acquisition of Medicago Inc. by MTPC. On September 18, 2013, 9284-9686 Québec Inc.,a subsidiary of MTPC, acquired all of the outstanding common shares of Medicago, other than the common shares currently held by MTPC and Philip Morris...

2013-09-12 08:30:10

QUEBEC CITY, Sept. 12, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company"), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), is pleased to announce that the Superior Court of Quebec has granted its final order approving the previously announced plan of arrangement (the "Arrangement") involving the Company, Mitsubishi Tanabe...

2013-09-10 08:29:18

BALTIMORE, Sept. 10, 2013 /PRNewswire/ -- Paragon Bioservices, a contract manufacturing organization whose expertise is the process development and manufacturing of biopharmaceuticals, announced today that it has been awarded the 2013 CMO Leadership Award for Quality and Reliability. "We are very honored to receive this award from Life Science Leader -- especially because this is our third consecutive year," said Dr Marco Chacon, Paragon's CEO. "For more than twenty years, we have...

2013-08-29 16:24:55

QUEBEC CITY, Aug. 29, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company"), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), during today's special meeting of shareholders of Medicago (the "Meeting"), is pleased to annouce that its shareholders have approved the resolution authorizing the previously announced plan of...

2013-08-09 16:22:47

QUEBEC CITY, Aug. 9, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced its operational and financial results for the second quarter ended June 30, 2013. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. Financial Results For the...